Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Improved survival seen with addition of abiraterone for patients receiving androgen deprivation therapy + docetaxel.

Add Yahoo as a preferred source to see more of our stories on Google. David James, a director at Prostate Cancer Research, says research and treatment advances mean that thousands of men with advanced ...

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread ...

What Prostate Cancer Survival Rates Tell Us Can Prostate Cancer Be Cured? Screening and Early Detection Lead to Better Survival Prostate cancer is the fourth most commonly diagnosed cancer worldwide, ...

If a person has an "aggressive" prostate cancer with a Gleason score of 9, what does that mean? What's the outlook when it comes to survival rate and prognosis? Every cancer survivor is unique, of ...

In a large study of older US adults, metabolic syndrome marked substantially poorer survival after breast or prostate cancer, highlighting the potential value of integrating metabolic health ...

Among patients with metastatic or very high-risk nonmetastatic prostate cancer, lower prostate-specific antigen (PSA) levels during hormone-based therapy — particularly ≤ 0.2 ng/mL — were strongly ...

Excess body weight, as measured by BMI, is associated with improved overall survival (OS) in men with advanced prostate cancer, particularly those with metastatic castration-resistant disease, a ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

U.S. pharmaceutical company Johnson & Johnson (J&J) is conducting clinical trials for its prostate cancer (prostate gland ...